References
Adler, R.A.: 1992, ‘Genome research: Fulfilling the public's expectation for knowledge and commercialisation’, Science257, pp. 908–914.
Advisory Committee on Genetic testing (ACGT): 1997, Code of Practice and Guidance on Human Genetic Testing Services Supplied Direct to the Public. London: Health Departments of the United Kingdom.
Anderson, C.: 1993, ‘Genome project goes commercial’, Science259, pp. 300–302.
Andrews, L.B. et al. (eds.): 1994, Assessing Genetic Risks: Implications for Health and Social Policy. Washington D.C.: Institute of Medicine, National Academy Press.
Anonymous: 1997, ‘Genomics wheelers and dealers’, Science275, pp. 774–775.
Beauchamp, T.L. and N.E. Bowie (eds): 1993, Ethical Theory and Business. Englewood Cliffs, New Jersey: Prentice Hall Inc.
Biesecker, B.B. et al.: 1993, ‘Genetic counselling for families with inherited susceptibility to breast and ovarian cancer’, Journal of the American Medical Association269, pp. 1970–1974.
Blumenthal, D.: 1992, ‘Academic-industry relationships in the life sciences’, Journal of the American Medical Association268, pp. 3344–3349.
Blumenthal, D. et al.: 1997, ‘Withholding research results in academic life science’, Journal of the American Medical Association227, pp. 1224–1228.
Boatright, J.R.: 1993, Ethics and the Conduct of Business. Englewood Cliffs, New Jersey: Prentice Hall.
Breo, D.L.: 1993, ‘Altered fates. Counselling families with inherited breast cancer’, Journal of the American Medical Association269, pp. 2017–2022.
Brower, V.: 1997, ‘Testing, testing... testing?’ Nature Medicine3, pp. 131–132.
Bull, S.: 1996, ‘Mail order gene testing’, Bulletin of Medical Ethics(February), pp. 20–21.
Burke, W. et al.: 1997, ‘Recommendations for follow-up of individuals with an inherited predisposition to cancer’, Journal of the American Medical Association277, pp. 997–1003.
Clarke, A. (ed.): 1994, ‘Introduction’. In: Genetic Counselling: Practice and Principles. London: Routledge.
Cohen, J.: 1997, ‘The genomics gamble’, Science275, pp. 767–772.
Danish Council of Ethics: 1993, Ethics and Mapping of the Human Genome. Copenhagen: Danish Council of Ethics.
Dausset, J.: 1996, ‘Predictive medicine’, European Journal of Obstetrics, Gynaecology and Reproductive Biology65, pp. 29–32.
Ducor, P.: 1997, ‘Are patents and research compatible’, Nature387 (1 May), pp. 13–14.
Editorial: 1996, ‘Capitalising on the genome’, Nature Genetics13, pp. 1–5.
Eisenberg, R.S.: 1992a, ‘Genes, patents, and product development’, Science257, pp. 903–908.
Eisenberg, R.S.: 1992b, ‘Patent rights in the human genome project’. In: Gene Mapping: Using Law and Ethics as Guides. New York: Oxford University Press.
Eisenberg, R.S.: 1997, ‘Structure and function in gene patenting’, Nature Genetics15, pp. 125–130.
Health Council of the Netherlands, Committee DNADiagnostics: 1998, DNA-Diagnostiek, Rijswijk: Health Council (1998/11).
Holtzman, N.A. and M.S. Watson: 1997, Promoting Safe and Effective Genetic testing in the United States, Final Report of the Task Force on Genetic testing. Baltimore: John Hopkins University Press.
Holtzman, N.A. et al.: 1997, ‘Predictive genetic testing: from basic research to clinical practice’, Science278, pp. 602–604.
Hubbard, R. and E. Wald: 1993, Exploding the Gene Myth: How Genetic Information is Produced and Manipulated by Scientists, Physicians, Employers, Insurance Companies, Educators and Law Enforcers. Boston: Beacon Press.
Jones, R.: 1996, ‘The impact of molecular medicine on health services’, Nature Medicine2, pp. 959–960.
Jonson, A.R. et al.: 1996, ‘The advent of the unpatients’, Nature Medicine2, pp. 622–624.
Joyce, C.: 1987, ‘Genes reach the medical market’, New Scientist115 (16 July), pp. 45–49.
Kahn, P.: 1996, ‘Coming to grips with genes and risk’, Science274, pp. 496–498.
King, M.C., S. Roweland and S.M. Love: 1993, ‘Inherited breast and ovarian cancer. What are the risks? What are the choices?’ Journal of the American Medical Association269, pp. 1975–1980.
Marcus, A.: 1996, ‘Owning a gene: patent pending’, Nature Medicine2, pp. 728–729.
Marshall, E.: 1996, ‘ELSI’s cystic fibrosis experiment’, Science274, p. 489.
Marshall, E.: 1997, ‘Is data-hoarding slowing the assault on pathogens?’ Science275, pp. 777–780.
Milunski, A.: 1992, ‘Threatened survival of academic-based genetic laboratory services’, American Journal of Human Genetics50, pp. 643–645.
Nuffield Council on Bioethics: 1993, Genetic Screening: Ethical Issues. London: Nuffield Council on Bioethics.
Roberts, L.: 1990, ‘To test or not to test?’ Science247, pp. 17–19.
Taupitz, J.: 1993, ‘Kommerzialisierung menschlicher Körpersubstanzen’. In: R. Damm and D. Hart (eds.), Rechtliche Regulierung von Gesundheidsrisiken. Baden-Baden: Nomos Verl. Ges., pp. 51–93.
Tibben, A.: 1993, What is Knowledge but Grieving? On Psychological Effects of Presymptomatic DNA-testing for Huntingdon’s Disease. Rotterdam: Universiteitsdrukkerij Erasmus.
Trigg, M.E. and M.R. Geier: 1992, ‘On the relationship between academic and private genetic services’, American Journal of Human Genetics51, pp. 890–891.
U.S. Congress, Office of Technology Assessment (OTA): 1991, Biotechnology in a Global Economy. Washington, D.C.: U.S. Government Printing Office.
Vallance, E.: 1995, Business Ethics at Work. Cambridge: Cambridge University Press.
Wilfond, B.S. and K. Nolan: 1993, ‘National policy development for the clinical application of genetic diagnostic services: lessons from cystic fibrosis’, Journal of the American Medical Association270, pp. 2948–2954.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hoedemaekers, R., ten Have, H. Commercialisation of genetic diagnostic services. Med Health Care Philos 1, 217–224 (1998). https://doi.org/10.1023/A:1009913008908
Issue Date:
DOI: https://doi.org/10.1023/A:1009913008908